Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus

Area of Science:

• Vascular Biology
• Rare Diseases
• Pharmacology

Background:

• Generalized lymphatic anomaly (GLA) is a rare, complex lymphatic malformation affecting soft tissues, spleen, and bones.
• GLA can cause significant morbidity, including focal skeletal fragility and pathological effusions.
• Current treatment options for GLA are limited, necessitating research into effective therapies.

Observation:

• A previous trial indicated partial response in GLA patients treated with sirolimus at a target trough level of 10-15 ng/mL for one year.
• This study explored the efficacy of a lower-dose, long-term sirolimus regimen for GLA.
• The treatment was administered over an extended period, focusing on sustained therapeutic levels.

Findings:

• Successful treatment of generalized lymphatic anomaly was achieved using a lower-dose, long-term sirolimus course.
• Patients demonstrated positive responses to the extended, reduced-dosage sirolimus therapy.
• The therapeutic approach proved effective in managing GLA symptoms and complications.

Implications:

• Low-dose, long-term sirolimus represents a viable and successful treatment strategy for generalized lymphatic anomaly.
• This approach may offer a more manageable and sustainable therapeutic option compared to higher-dose regimens.
• Further research into long-term outcomes and optimal dosing for GLA is warranted.